FAK

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Strategic management, Diagnosis, Initiation, Research and development, Conference, Immunotherapy, Part, FAK, New Drug Application, Patient, Cancer, RAMP, Accelerated approval (FDA), NDA, Table, SGO, BRAF, Society, IND, Abstract, Bank statement, AACR, Pancreatic cancer, Investment, Verastem Oncology, MEK, Therapy, Safety, GAAP, Gynecologic Oncology (journal), Food, FDA, Annual general meeting, Pharmaceutical industry

Verastem Oncology ended the fourth quarter of 2023 with cash, cash equivalents and investments of $137.1 million.

Key Points: 
  • Verastem Oncology ended the fourth quarter of 2023 with cash, cash equivalents and investments of $137.1 million.
  • Research & development expenses for the 2023 Quarter were $22.5 million, compared to $10.7 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $8.6 million, compared to $6.1 million for the 2022 Quarter.
  • These non-GAAP financial measures exclude certain amounts or expenses from the corresponding financial measures determined in accordance with GAAP.

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Retrieved on: 
Monday, March 11, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, FAK, Patient, Research, RAMP, Cancer, SGO, Society, Woman, Clinical trial, Verastem Oncology, DRS, MEK, Gynecologic Oncology (journal), Consultant, Annual general meeting, Pharmaceutical industry

Verastem will have an exhibition booth (#420) at the meeting to provide an overview of its ongoing cancer research.

Key Points: 
  • Verastem will have an exhibition booth (#420) at the meeting to provide an overview of its ongoing cancer research.
  • “In addition, the plenary oral presentation highlighting preclinical efficacy of avutometinib in combination with a FAK inhibitor reinforces the potential of this combination in low-grade serous ovarian cancer regardless of KRAS status.
  • Banerjee and Grisham are paid consultants for Verastem Oncology.
  • The multinational survey is supported by Verastem Oncology.

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Tuesday, March 5, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NRAS, Woman, Recurrence, Food, Pain, FAK, ODD, Verastem Oncology, Accelerated approval (FDA), Patient, Survival, Disease, NDA, Cancer, Pharmaceutical industry

“The FDA Orphan Drug Designation for avutometinib alone or in combination with defactinib in low-grade serous ovarian cancer is an important step in recognizing this rare cancer as a distinct disease that currently has no FDA-approved treatments,” said Dan Paterson, president and chief executive officer of Verastem Oncology.

Key Points: 
  • “The FDA Orphan Drug Designation for avutometinib alone or in combination with defactinib in low-grade serous ovarian cancer is an important step in recognizing this rare cancer as a distinct disease that currently has no FDA-approved treatments,” said Dan Paterson, president and chief executive officer of Verastem Oncology.
  • “We are rapidly advancing the development program for avutometinib and defactinib in low-grade serous ovarian cancer with our ongoing Phase 3 clinical trial to deliver this new combination treatment to patients as quickly as possible.
  • LGSOC is a highly recurrent, chemotherapy-resistant cancer, associated with slow tumor growth and high mortality rate.
  • While chemotherapy is the standard of care for this disease, there are no treatments specifically approved by the FDA to treat LGSOC.

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, BRAF, Immunotherapy, RAMP, FAK, AACR, University, RAF, Verastem Oncology, PDAC, Patient, IND, Cancer, MEK, Pharmaceutical industry

The presentations will highlight anti-tumor efficacy of GFH375 (VS-7375), a potent and selective orally bioavailable KRAS G12D (ON/OFF) inhibitor, and will also show data of RAF/MEK clamp plus FAK inhibition in pancreatic ductal adenocarcinoma (PDAC) models supporting the ongoing RAMP 205 trial.

Key Points: 
  • The presentations will highlight anti-tumor efficacy of GFH375 (VS-7375), a potent and selective orally bioavailable KRAS G12D (ON/OFF) inhibitor, and will also show data of RAF/MEK clamp plus FAK inhibition in pancreatic ductal adenocarcinoma (PDAC) models supporting the ongoing RAMP 205 trial.
  • Additional presentations will support the use of avutometinib and FAK inhibitor combination in cutaneous melanoma models to overcome resistance to BRAF and MEK inhibitors, resistance to immunotherapy, and brain metastasis.
  • “For the first time, GenFleet and Verastem will present potency, selectivity, anti-tumor efficacy, and bioavailability data on GFH375 (VS-7375), a potential best-in-class orally active KRAS G12D (ON/OFF) inhibitor.
  • We look forward to an IND submission by GenFleet in China in H1 2024,” said Jonathan Pachter, Ph.D., chief scientific officer of Verastem Oncology.

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

Retrieved on: 
Thursday, October 19, 2023
Neoplasm, Fibroblast, IND, Ovarian cancer, Human, Gastrointestinal cancer, PFS, Conference, TNBC, Tissue, ADC, Pancreatic tumor, Spacecraft, Pancreatic cancer, PDX, FAK, CAF, Pharmaceutical industry, Medical imaging

Meanwhile, one critical factor limiting ADC effectiveness is poor access to tumor cells, especially in high stroma tumors such as pancreatic tumor, TNBC etc.

Key Points: 
  • Meanwhile, one critical factor limiting ADC effectiveness is poor access to tumor cells, especially in high stroma tumors such as pancreatic tumor, TNBC etc.
  • Preclinical data demonstrated that IN10018 was able to break down the fibrotic barrier, improving penetration of large molecules including ADC.
  • Significant synergy was observed between IN10018 and ADCs such as Enhertu and Trodelvy in stroma rich tumors including pancreatic cancer, TNBC, and ovarian cancer models.
  • The company is establishing collaborations with ADC companies and welcomes more collaborations against deadly high stroma tumors.

CN Announces Upgrade to Falcon Premium Intermodal Service

Retrieved on: 
Tuesday, September 12, 2023
CNR, Food, Union Pacific Railroad, National Railway Company of Cuba, Canadian National Railway, CN, Eagle Pass, Falcon, TSX, Growth, FAK, CNI, NYSE, Rail freight transport

MONTREAL, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Canadian National Railway Company (CN) (TSX: CNR) (NYSE: CNI), today announced an upgrade to its Falcon Premium Intermodal Service.

Key Points: 
  • MONTREAL, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Canadian National Railway Company (CN) (TSX: CNR) (NYSE: CNI), today announced an upgrade to its Falcon Premium Intermodal Service.
  • “CN is pleased to offer customers an entire day off the already fast Falcon Intermodal Premium Service,” said CN President and Chief Executive Officer Tracy Robinson.
  • “I am confident the early results of the Falcon service, combined with our speed and reliability, will enable the continued growth of this service.”
    The Falcon Premium Intermodal Service is a best-in-class Mexico-US-Canada service with a seamless rail connection in Chicago, Illinois.
  • Falcon Premium intermodal service also contributes to lower greenhouse gas emissions through reduced rail miles and truck-to-rail conversion.

Union Pacific's Newest Offering Removes Full Day of Transit Between the U.S., Mexico and Canada, Creating Unmatched Service for Customers

Retrieved on: 
Tuesday, September 12, 2023
Cumulative elevation gain, Morgan Stanley, Union Pacific Bridge, Grupo México, Food, Comparison of multi-paradigm programming languages, Union Pacific Railroad, Eagle, CN, Marketing, Eagle Pass, Guanajuato, Vena, FAK, Growth, City, Conference, Rail freight transport, Airline

OMAHA, Neb., Sept. 12, 2023 /PRNewswire/ -- Union Pacific CEO Jim Vena announced today at Morgan Stanley's 11th Annual Laguna Conference that the railroad's Mexico intermodal products – Eagle and Falcon Premium – create unmatched intermodal services, connecting the United States, Mexico and Canada.

Key Points: 
  • Union Pacific recently removed a full day of transit time for customers shipping on Eagle and Falcon Premium.
  • Eagle Premium delivers seamless interchange between Mexico, Chicago, the West Coast, and eastern U.S. points, including Detroit, Michigan and Louisville, Kentucky.
  • Falcon Premium, developed jointly with Canadian National (CN) and Grupo Mexico (GMXT), serves all CN points within Canada and Detroit, Michigan.
  • "Union Pacific has a great network, and we will continue leveraging it to offer our customers competitive, world-class service," said Vena.

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Retrieved on: 
Tuesday, June 6, 2023
PRS, PD, Diarrhea, Cohort, American Society of Clinical Oncology, DCR, Cancer, Trae tha Truth, Pharmacokinetics, Sun, TKI, CHB, NSCLC, Lung cancer, Sun Yat-sen University Cancer Center, Female, ASCO, Vomiting, ORR, Drug resistance, Patient, Annual general meeting, Nausea, ALT, FAK, Poster, Principal, Notifiable disease, AST, Society, Landing slot, SD, Hepatitis, PR, Safety, ALK, Pharmaceutical industry

Among these results, the updated clinical data of APG-2449 showed the potential as a new treatment option that can effectively overcome drug resistance through the targeted inhibition of FAK.

Key Points: 
  • Among these results, the updated clinical data of APG-2449 showed the potential as a new treatment option that can effectively overcome drug resistance through the targeted inhibition of FAK.
  • Developed by Ascentage Pharma, APG-2449 is an orally available, small-molecule FAK/ALK/ROS1 TKI and the first China-developed third-generation ALK inhibitor entering clinical development.
  • "We believe that FAK inhibition could be a new treatment strategy for patients with NSCLC resistant to second-generation ALK inhibitors."
  • Appendix: The four posters on Ascentage Pharma's four lead drug candidates, including APG-2449, presented at this year's ASCO Annual Meeting.

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference

Retrieved on: 
Friday, May 26, 2023
TKI, CXCR4, PD, Cohort, SDH, Arrhythmia, Patient, AST, Landing slot, Thrombocytopenia, Fatigue, Disease, ALK, GIST, Male, PRS, Diarrhea, Arm, Pharmacokinetics, Mutation, Vomiting, ALT, Leukopenia, PR, Safety, Neutropenia, AE, Pulmonary embolism, Dehydration, Aes, DLT, DDI, Multimedia, NSCLC, MTTR, Immunotherapy, CBR, Anemia, CR, FAK, Pembrolizumab, ORR, Joint effusion, Electrolyte, Armed Forces Health Longitudinal Technology Application, PK, Rituximab, PM, Phosphorylation, IO, DCR, TLS, Weight loss, Trae tha Truth, Septic shock, WM, Thrombosis, Kidney, Nausea, AM, Recurrence, SD, QOD, Female, Powder metallurgy, Pharmaceutical industry, Nursing, PBMC

As of December 9, 2022, 130 patients were enrolled and treated with APG-2449 at doses ranging from 900 to1,500 mg.

Key Points: 
  • As of December 9, 2022, 130 patients were enrolled and treated with APG-2449 at doses ranging from 900 to1,500 mg.
  • Meanwhile, patients with higher pFAK expression in tumor tissues at baseline tended to achieve better clinical responses than those with lower pFAK expression after APG-2449 treatment.
  • Efficacy Results: The median duration of treatment in the 20 patients with SDH-deficient GIST was 7.8 (1.81-42.3) months.
  • Conclusions: Alrizomadlin combined with pembrolizumab is well tolerated and demonstrates clinical efficacy in patients with cutaneous melanoma that had progressed on PD-1/PD-L1 immunotherapy.

CN, UP, and GMXT Announce New Transformational Mexico-US-Canada Intermodal Service

Retrieved on: 
Monday, April 24, 2023
CNR, Food, UNP, BMV, Premium, CN, Eagle Pass, Falcon, TSX, FAK, CNI, Union Pacific Railroad, NYSE, Rail freight transport

MONTREAL, April 24, 2023 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) Union Pacific Railroad (NYSE: UNP) and GMXT (BMV: GMXT) proudly announced today the creation of Falcon Premium intermodal service, a best-in-class Mexico-US-Canada service with a seamless rail connection in Chicago, Illinois.

Key Points: 
  • MONTREAL, April 24, 2023 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) Union Pacific Railroad (NYSE: UNP) and GMXT (BMV: GMXT) proudly announced today the creation of Falcon Premium intermodal service, a best-in-class Mexico-US-Canada service with a seamless rail connection in Chicago, Illinois.
  • This service will directly benefit intermodal customers shipping automotive parts, food, FAK (freight all kinds), home appliances, and temperature-controlled products.
  • Falcon Premium service will be the fastest, most reliable intermodal rail service between Canada and Mexico by combining the unique benefits of each partner.
  • Falcon Premium intermodal service will also contribute to lower greenhouse gas emissions through reduced rail miles and significant truck-to-rail conversion.